|
Market Cap (6-Jul) TBC |
Close (30-Jun) $0.059 |
Volume (30-Jun) 4,352,698 |
Shortsold (24-Jul) 256 (0.00%) (719th) |
|
52w High $0.000 |
52w Low $0.000 |
P/E - |
EPS - |
ANP released this announcement to the ASX on 29 October 2020, 16:52. The announcement is not marked as price sensitive, and is 60 page(s) in length and 3.53MB in size.
You can view all announcements from ANP and see how they appear on a price chart on the announcements page.
At the date of this announcement, ANP was 0.000% short sold according to ASIC data. It was ranked the 578th most shorted stock on the ASX. It remains ranked 719th as of the latest reported data (24 July 2023).
| Other Recent Announcements from ANP | |
|---|---|
| MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK | 27 June 2023, 15:46 |
| First Patient Dosed in ATL1102 Phase IIb DMD Trial | 8 June 2023, 8:38 |
| Shareholder Newsletter | 6 June 2023, 15:47 |
| Annual Report | 29 October 2020, 16:52 |
| ANP receives US FDA ODD for ATL1102 in DMD | 26 October 2020, 8:51 |
| Trading Halt | 22 October 2020, 15:20 |
| Pause in Trading | 22 October 2020, 14:59 |
You must be logged in to post a reply.
Antisense Therapeutics 